The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's Rybrevant in combination with lazertinib as a chemotherapy-free first-line treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. This approval positions J&J's therapy as a direct competitor to AstraZeneca's Tagrisso, a widely used treatment for this patient group. Rybrevant disrupts the growth of EGFR and MET genes, while lazertinib inhibits rapid cell reproduction, offering an effective alternative to chemotherapy-based regimens.
This FDA decision is backed by a late-stage study that demonstrated the Rybrevant combination's ability to extend progression-free survival compared to Tagrisso. The approval allows J&J to strengthen its oncology portfolio, particularly in the NSCLC segment, where Rybrevant has already been used as a monotherapy and in combination with chemotherapy for patients whose disease has progressed. The combination treatment is expected to significantly impact the market, with J&J anticipating over $5 billion in peak sales for Rybrevant.
AstraZeneca's Tagrisso remains a major player in the NSCLC market, generating $5.8 billion in sales last year. However, J&J's newly approved combination therapy presents a formidable challenge by offering patients an effective, chemotherapy-free option, potentially shifting the standard of care for EGFR-mutated NSCLC.
Click here to read the original news story.